Cargando…

Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature

With the advent of potent second-line anti-androgen therapy, we and others have observed an increased incidence of androgen receptor (AR)-null small cell or neuroendocrine prostate cancer (SCNPC) in metastatic castration-resistant prostate cancer (mCRPC). Our study was designed to determine the effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labrecque, Mark P., Brown, Lisha G., Coleman, Ilsa M., Nguyen, Holly M., Lin, Daniel W., Corey, Eva, Nelson, Peter S., Morrissey, Colm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817027/ https://www.ncbi.nlm.nih.gov/pubmed/33471819 http://dx.doi.org/10.1371/journal.pone.0245602

Ejemplares similares

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
por: Nguyen, Holly M., et al.
Publicado: (2017)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy
por: Ruppender, Nazanin, et al.
Publicado: (2015)

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
por: Morrissey, Colm, et al.
Publicado: (2007)

Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4
por: Coleman, Daniel J., et al.
Publicado: (2020)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
por: Sychev, Zoi E., et al.
Publicado: (2023)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
por: Cejas, Paloma, et al.
Publicado: (2021)

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
por: Baca, Sylvan C., et al.
Publicado: (2021)

Single cell transcriptomic analysis of prostate cancer cells
por: Welty, Christopher J, et al.
Publicado: (2013)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
por: Pritchard, Colin C., et al.
Publicado: (2014)

Zebrafish functional xenograft vasculature platform identifies PF-502 as a durable vasculature normalization drug
por: Zhong, Jian, et al.
Publicado: (2023)

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
por: Sun, Yinggang, et al.
Publicado: (2015)

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
por: Brennen, W. Nathaniel, et al.
Publicado: (2021)

Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts.
por: Bussink, J., et al.
Publicado: (1998)

Origin of the vasculature supporting growth of primary patient tumor xenografts
por: Hylander, Bonnie L, et al.
Publicado: (2013)

The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity
por: Storck, William K., et al.
Publicado: (2022)

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways
por: Chéry, Lisly, et al.
Publicado: (2014)

Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
por: Brady, Lauren, et al.
Publicado: (2021)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
por: Kumar, Shreya, et al.
Publicado: (2023)

Developing a xenograft model of human vasculature in the mouse ear pinna
por: Meehan, Gavin R., et al.
Publicado: (2020)

Conditional ablation of macrophages disrupts ovarian vasculature
por: Turner, Emily C, et al.
Publicado: (2011)

Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth
por: Gritsina, Galina, et al.
Publicado: (2023)

The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts
por: Fung, Andrea S, et al.
Publicado: (2015)

Effect of Ultrasound‐Stimulated Microbubbles and Hyperthermia on Tumor Vasculature of Breast Cancer Xenograft
por: Sharma, Deepa, et al.
Publicado: (2022)

Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors
por: Drees, Jeremy J., et al.
Publicado: (2015)

Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development
por: Ci, Xinpei, et al.
Publicado: (2020)

Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer
por: Kumar, Akash, et al.
Publicado: (2016)

Genetic background influences murine prostate gene expression: implications for cancer phenotypes
por: Bianchi-Frias, Daniella, et al.
Publicado: (2007)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia
por: Melong, Nicole, et al.
Publicado: (2017)

Imaging of Neuroendocrine Prostatic Carcinoma
por: Taher, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tuhsunhubmvt7h6q7bvjonemoo